Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011-2020): Current Status and Future Prospects

被引:36
作者
El-Gamal, Mohammed I. [1 ,2 ,3 ]
Zaraei, Seyed-Omar [2 ]
Madkour, Moustafa M. [2 ]
Anbar, Hanan S. [4 ]
机构
[1] Univ Sharjah, Dept Med Chem, Coll Pharm, Sharjah 27272, U Arab Emirates
[2] Univ Sharjah, Sharjah Inst Med Res, Sharjah 27272, U Arab Emirates
[3] Univ Mansoura, Dept Med Chem, Fac Pharm, Mansoura 35516, Egypt
[4] Dubai Pharm Coll Girls, Dept Clin Pharm & Pharmacotherapeut, Dubai 19099, Egypt
关键词
anticancer; anti-inflammatory; kinase inhibitor; neurodegenerative disorders; pyrazole; 2; CHK2; INHIBITORS; BIOLOGICAL EVALUATION; ANTIPROLIFERATIVE ACTIVITY; HIGHLY POTENT; SELECTIVE INHIBITOR; MOLECULAR DOCKING; DUAL INHIBITORS; RAF KINASE; DERIVATIVES; DESIGN;
D O I
10.3390/molecules27010330
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pyrazole has been recognized as a pharmacologically important privileged scaffold whose derivatives produce almost all types of pharmacological activities and have attracted much attention in the last decades. Of the various pyrazole derivatives reported as potential therapeutic agents, this article focuses on pyrazole-based kinase inhibitors. Pyrazole-possessing kinase inhibitors play a crucial role in various disease areas, especially in many cancer types such as lymphoma, breast cancer, melanoma, cervical cancer, and others in addition to inflammation and neurodegenerative disorders. In this article, we reviewed the structural and biological characteristics of the pyrazole derivatives recently reported as kinase inhibitors and classified them according to their target kinases in a chronological order. We reviewed the reports including pyrazole derivatives as kinase inhibitors published during the past decade (2011-2020).
引用
收藏
页数:85
相关论文
共 111 条
[1]  
A Phase I, 1 MAN STUDY EVALUATE
[2]   Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran-pyrazole derivatives as anticancer agents [J].
Abd El-Karim, Somaia S. ;
Anwar, Manal M. ;
Mohamed, Neama A. ;
Nasr, Tamer ;
Elseginy, Samia A. .
BIOORGANIC CHEMISTRY, 2015, 63 :1-12
[3]   Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety [J].
Abdel-Maksoud, Mohammed S. ;
El-Gamal, Mohammed I. ;
El-Din, Mahmoud M. Gamal ;
Oh, Chang Hyun .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 34 (01) :97-109
[4]   Tri- and Tetrasubstituted Pyrazole Derivates: Regioisomerism Switches Activity from p38MAP Kinase to Important Cancer Kinases [J].
Abu Thaher, Bassam ;
Arnsmann, Martina ;
Totzke, Frank ;
Ehlert, Jan E. ;
Kubbutat, Michael H. G. ;
Schaechtele, Christoph ;
Zimmermann, Markus O. ;
Koch, Pierre ;
Boeckler, Frank M. ;
Laufer, Stefan A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (02) :961-965
[5]  
[Anonymous], Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - Full Text View - ClinicalTrials.gov
[6]  
[Anonymous], SEARCH RESULTS TERM
[7]   7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent [J].
Bavetsias, Vassilios ;
Perez-Fuertes, Yolanda ;
McIntyre, Patrick J. ;
Atrash, Butrus ;
Kosmopoulou, Magda ;
O'Fee, Lisa ;
Burke, Rosemary ;
Sun, Chongbo ;
Faisal, Amir ;
Bush, Katherine ;
Avery, Sian ;
Henley, Alan ;
Raynaud, Florence I. ;
Linardopoulos, Spiros ;
Bayliss, Richard ;
Blagg, Julian .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (19) :4203-4209
[8]   Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo [J].
Burch, Jason D. ;
Barrett, Kathy ;
Chen, Yuan ;
DeVoss, Jason ;
Eigenbrot, Charles ;
Goldsmith, Richard ;
Ismaili, M. Hicham A. ;
Lau, Kevin ;
Lin, Zhonghua ;
Ortwine, Daniel F. ;
Zarrin, Ali A. ;
McEwan, Paul A. ;
Barker, John J. ;
Ellebrandt, Claire ;
Kordt, Daniel ;
Stein, Daniel B. ;
Wang, Xiaolu ;
Chen, Yong ;
Hu, Baihua ;
Xu, Xiaofeng ;
Yuen, Po-Wai ;
Zhang, Yamin ;
Pei, Zhonghua .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (09) :3806-3816
[9]   Property- and Structure-Guided Discovery of a Tetrahydroindazole Series of Interleukin-2 Inducible T-Cell Kinase Inhibitors [J].
Burch, Jason D. ;
Lau, Kevin ;
Barker, John J. ;
Brookfield, Fred ;
Chen, Yong ;
Chen, Yuan ;
Eigenbrot, Charles ;
Ellebrandt, Claire ;
Ismaili, M. Hicham A. ;
Johnson, Adam ;
Kordt, Daniel ;
MacKinnon, Colin H. ;
McEwan, Paul A. ;
Ortwine, Daniel F. ;
Stein, Daniel B. ;
Wang, Xiaolu ;
Winkler, Dirk ;
Yuen, Po-Wai ;
Zhang, Yamin ;
Zarrin, Ali A. ;
Pei, Zhonghua .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (13) :5714-5727
[10]   Investigation of the Differences in Activity between Hydroxycycloalkyl N1 Substituted Pyrazole Derivatives As Inhibitors of B-Raf Kinase by Using Docking, Molecular Dynamics, QM/MM, and Fragment-Based De Novo Design: Study of Binding Mode of Diastereomer Compounds [J].
Caballero, Julio ;
Alzate-Morales, Jans H. ;
Vergara-Jaque, Ariela .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2011, 51 (11) :2920-2931